Structural bioinformatics-based identification of EGFR inhibitor gefitinib as a putative lead compound for BACE. (Q39025002)

8 September 2017

title

Structural bioinformatics-based identification of EGFR inhibitor gefitinib as a putative lead compound for BACE. (English)

1 reference

8 September 2017

1 reference

Mingshan Niu

1 reference

8 September 2017

Jin Hu

1 reference

8 September 2017

Sijin Wu

1 reference

8 September 2017

Zhang Xiaoe

1 reference

8 September 2017

Huaxi Xu

1 reference

8 September 2017

Yunwu Zhang

1 reference

8 September 2017

Jie Zhang

1 reference

8 September 2017

Yongliang Yang

1 reference

8 September 2017

publication date

1 January 2014

1 reference

Chemical Biology and Drug Design

8 September 2017

published in

1 reference

8 September 2017

1 reference

8 September 2017

1 reference

8 September 2017

page(s)

81-88

1 reference

A century of Alzheimer's disease

8 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FCBDD.12200

Amyloid deposition as the central event in the aetiology of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FCBDD.12200

The Alzheimer's disease beta-secretase enzyme, BACE1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FCBDD.12200

Beta-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FCBDD.12200

BACE1: the beta-secretase enzyme in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FCBDD.12200

The amyloid cascade hypothesis for Alzheimer's disease: an appraisal for the development of therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FCBDD.12200

Developing β-secretase inhibitors for treatment of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FCBDD.12200

Spirocyclic sulfamides as β-secretase 1 (BACE-1) inhibitors for the treatment of Alzheimer's disease: utilization of structure based drug design, WaterMap, and CNS penetration studies to identify centrally efficacious inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FCBDD.12200

21 January 2018

New uses for old drugs

1 reference

https://api.crossref.org/works/10.1111%2FCBDD.12200

The challenge of new drug discovery for tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FCBDD.12200

ApoE-directed therapeutics rapidly clear β-amyloid and reverse deficits in AD mouse models

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FCBDD.12200

The anticancer multi-kinase inhibitor dovitinib also targets topoisomerase I and topoisomerase II.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FCBDD.12200

Drug Discovery Using Chemical Systems Biology: Weak Inhibition of Multiple Kinases May Contribute to the Anti-Cancer Effect of Nelfinavir

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FCBDD.12200

UCSF Chimera--a visualization system for exploratory research and analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FCBDD.12200

Structure-based systems biology for analyzing off-target binding

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FCBDD.12200

TM-align: a protein structure alignment algorithm based on the TM-score

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FCBDD.12200

SMAP-WS: a parallel web service for structural proteome-wide ligand-binding site comparison

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FCBDD.12200

Endoplasmic reticulum and trans-Golgi network generate distinct populations of Alzheimer beta-amyloid peptides

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FCBDD.12200

Differential levels of alpha-synuclein, beta-amyloid42 and tau in CSF between patients with dementia with Lewy bodies and Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FCBDD.12200

A semiempirical free energy force field with charge-based desolvation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FCBDD.12200

Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FCBDD.12200

A unified statistical model to support local sequence order independent similarity searching for ligand-binding sites and its application to genome-based drug discovery

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FCBDD.12200

Epidermal growth factor receptor is a preferred target for treating amyloid-β-induced memory loss

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FCBDD.12200

21 January 2018

Identifiers

DOI

10.1111/CBDD.12200

1 reference

8 September 2017

1 reference